Early Parkinson Disease

Publication Date: November 16, 2021

Key Points

Key Points

  • The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
  • The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.

Treatment

...eatment...

...pa vs. DAs vs. MAO-B inhibitors...

...ld counsel patients with early PD on the benefit...

...n patients with early PD who seek tre...

...ay prescribe DAs as the initial do...

Clinicians should not prescribe DAs to patients...


...ribing levodopa...

...ould initially prescribe immediate...

...th early PD, clinicians should prescr...

...ld routinely monitor patients taking levodopa...

...ans should counsel patients taking levodopa tha...

...ould counsel patients that in later disease stag...


...escribing DAs...

...should inform the patient and care...

...d screen patients for cognitive impairment,...

...ians should screen patients for the presence...

...ld involve caregivers in assessments for ICDs,...

...s may screen patients for the presence of...

...ians should integrate patient preferenc...

...ians should prescribe the lowest dos...


Tapering and Discontinuing DA...

...cians should recommend tapering or disco...

...n DAs must be discontinued due to adver...


...cribing MAO-B inhib...

...icians should counsel patients with early...

...y prescribe MAO-B inhibitors as the initial d...


...cations for Parkinson DiseaseHaving...